10/2/24, 8:13 PM SOP for Stability Program

PHARMA SOP
WORLD
Home About Contact    

QA QC MICRO PROD WAREHOUSE PHARMACOPOEIA METHOD VAL VALIDATIONS GUIDELINES  ENG 

Home  QA-SOP  SOP for Stability Program

Social Plugin

SOP for Stability Program

 Facebook  Twitter
 srikanth nagabiru  July 16, 2023
 Instagram  VKontakte

1.0 OBJECTIVE:

To describe the procedure for conducting stability studies for the drug products in order to establish appropriate expiration and
storage condition. Search This Blog

Search this blog Search

Featured Post

Sterility Test validation

 srikanth nagabiru  September 30, 2023

PROTOCOL APPROVAL Signing of this approval page of protocol

2.0 SCOPE: indicates agreement with…

The scope of this SOP is to provide the procedure for stability Study initiation, monitoring, collection of sample and compilation
of stability data. Hot Posts

Peak-Valley Ratio calculation

3.0 RESPONSIBILITY:
 November 25, 2012

3.1 Quality Assurance personnel to coordinate stability study. Responsibility of Stability coordinator as per Annexure – 7

USP 2023[USP 46 and NF 41

3.2 Analyst(s) for analysing the stability samples.
 July 26, 2023

3.3 Raw Material store personnel to intimate QA Department regarding Active pharmaceutical ingredient (API) received from
new vendor. Performance qualification of
HVAC/AHU
3.4 Head QA to ensure the compliance.  November 29, 2012

4.0 PROCEDURE: Revised Schedule M

 May 22, 2024

4.1 REASONS FOR CONDUCTING STABILITY STUDIES

British Pharmacopoeia 2023

The stability study shall be performed for the following reasons:
 November 02, 2023

4.1.1 Introduction of new product/new process.

SOP for investigation of product for

4.1.2 Change in the manufacturing process / critical process parameters, Significant change in the batch size. physical defects in tablets
 May 27, 2023

4.1.3 Change in critical equipment of the manufacturing process.

Retention sample or Control samples
4.1.4 Change in container and closure. management sop
 July 23, 2023

4.1.5 Reprocessing for the first time.

Blender capacity Calculation
 October 06, 2023
4.1.6 Change in Composition and Component of drug product.

4.1.7 Change in facility/location. Join us

Operation, Calibration and Maintenance, of
Sonicator
4.1.8 For regulatory purposes.  November 17, 2022

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 1/13
10/2/24, 8:13 PM SOP for Stability Program
4.1.9 Change in the storage conditions.

4.2 SELECTION OF BATCHES:

Cleaning Validation Calculations-

The following procedures shall be followed for the selection of batches, for stability studies:
Maximum Allowable Carryover[MACO]
 September 29, 2012
4.2.1 New product / new process:

4.2.1.1 Bio batch (Exhibit batch) shall be kept in stability as per the requirement and first three validation batches shall be kept Random Posts
in stability.

DEVIATIONS HANDLING IN PHARMACEUTICALS

4.2.1.2 In case of product for domestic market after the process optimization, 3 successive commercial batches shall be kept 06.12.2022 - 0 Comments
at all three conditions mentioned below. 1.0 OBJECTIVETo lay down a procedure for
identification, review, preventing and closure of
deviations…

– Accelerated conditions of 40°C ± 2°C / 75% RH ± 5% RH

DISPOSAL OF EXCESS SAMPLES, EXPIRED
CHEMICALS, IMPURITIES, REFERENCE STANDARDS
– *Long term conditions of 25°C + 2°C / 60% RH ± 5% RH AND EMPTY REAGENT BOTTLES OR SOLVENT
BOTTLES OR CONTAINERS
or 30°C + 2°C / 65% RH ± 5% RH 20.11.2022 - 0 Comments
1.0 OBJECTIVE To lay down a procedure for the Disposal of Excess
samples, Expired chemicals, Impurities,…
– **Intermediate conditions of 30°C + 2°C / 65% RH ± 5% RH or as per the regulatory requirements.
GUIDELINES FOR STABILITY TESTING OF ACTIVE
PHARMACEUTICAL INGREDIENTS AND FINISHED
* It is as per recommended storage condition whether long term stability studies are performed at 25°C + 2°C / 60% RH ± 5%
PHARMACEUTICAL PRODUCTS(SFDA)
RH or 30°C + 2°C / 65% RH ± 5% RH. 07.11.2022 - 0 Comments
Guidelines for Stability Testing of Active
Pharmaceutical Ingredients and Finished Pharmaceutical ProductsThe…
** if 30°C + 2°C / 65% RH ± 5% RH is long term condition, there is no intermediate condition.

DETERMINATION OF EPLERENONE TABLET

4.2.1.3 In case, the product by nature is known to be temperature sensitive, the storage conditions shall be different. This shall (25/50MG) BY UV SPECTROPHOMETRIC METHOD
be appropriately decided by QA in consultation with R&D and Regulatory Affairs. 19.11.2022 - 0 Comments
1.0 OBJECTIVE To provide the…

4.2.1.4 Regular study – Anyone from the first three batch of the year and any one from the first three batches after every 100th
batch in a year shall be kept for long term stability study. PREPARATION AND STANDARDIZATION OF 0.1M
AMMONIUM THIOCYANATE
02.12.2012 - Comments Disabled
4.2.2 Major Process/ Equipment Change (After regularization) Normal 0 false false false EN-US X-NONE X-NONE …

After a major change in manufacturing process or critical equipment, which warrants stability study requirement, three
production batches shall kept for stability study in accelerated, intermediate and long-term condition.
Categories
4.2.3 Change in batch size
 ANALYTICAL METHODS 51 POSTS
After a significant change in batch size, which warrants stability study requirement, one production batch shall kept for stability
study in accelerated, intermediate and long-term condition.
 AR&D 14 POSTS

4.2.4 Change in container and closure:

 BOOKS 10 POSTS

The stability study shall be carried out for change in container and closure of drug products as per Annexure 13.
 DATA INTEGRITY 4 POSTS

Type 0, Type 1, Type 2, Type 3 are data packages which is required as per Annexure 14

 FR&D 1 POSTS
4.2.5 Reprocessing

 GUIDELINES 46 POSTS
In case Reprocessing for a product is performed for the first time, the

reprocessed batch, shall be kept on accelerated stability study and long term  METHOD VALIDATION 18 POSTS

Stability study.  MICROBIOLOGY 31 POSTS

4.2.6 Change in Composition and Component of drug product:  PHARMACOPOEA 22 POSTS

Level 1: Those that are unlikely to have any detectable impact on formulation quality and performance.
 PRODUCTION 51 POSTS

E.g. Partial deletion or addition of ingredient quantity, color, flavor.

 QA-SOP 70 POSTS

Change in excipients less than or equal to the following percentage.

 QUALITY CONTROL 51 POSTS

These percentage are based on 100% label claimed formulation. Total change shall not be more than 5%.

 QUIZ 1 POSTS
Onebatch shall be kept for stability study in long-term condition in case of level 1 change.

 STABILITY DATA EVALUATION 1 POSTS

Level 2: Change those that could have significant impact on formulation quality and performance

E.g. a. change in technical grade of excipients, partial change in excipients percentage of total formulation, greater than those  STABILITY GUIDELINES 6 POSTS

listed above for a level 1 change but less than or equal to following percentage.
 STABILITY STUDIES 1 POSTS
Join us
These percentage are based on 100% label claimed formulation. Total change shall not be more than 10%.

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 2/13
10/2/24, 8:13 PM SOP for Stability Program
b. Change in the vendor source of active pharmaceutical ingredient
 STRESS TESTING 1 POSTS

One batch shall be kept for stability study in accelerated and long-term condition in case of level 2 change.
 VALIDATION 6 POSTS

Note: Raw material store personnel shall give intimation for vendor change of API in existing product as per Annexure 12 to QA
Department and the intimation shall be in duplicate. One copy shall remain with store and one copy shall handed over to QA
 VOLUMETRIC SOLUTIONS 15 POSTS
department.

Level 3: Changes are those that are likely to have a significant impact on formulation quality and performance.

E.g. Any change beyond defined in level 1 with narrow therapeutic drug, Changes in the excipients ranges of all drug beyond
those defined in level 2 E.g. , a. One batch shall kept for stability study in accelerated and long-term condition in case of level 3
change.

4.3 STABILITY STUDY CONDITIONS / INTERVALS

@ At accelerated Storage condition, a minimum of three time points, including the initial and final time points (e.g., 0, 3 and 6
month)

$ Intermediate storage condition is called for as a result of significant change at the accelerated storage condition, a minimum
of four time points, including the initial and final time points (e.g. 0, 6, 9, 12 months)

NOTE : 1).Bulk pack in which there is a requirement of repackaging, stability study shall be performed at accelerated condition
for 1 month and long term condition for 3 months (Frequency: Initial & 3 months)

2) After getting the result of analysis from Analyst(s) if there is delay (By more than one month) in loading the samples in
stability chamber reanalysis shall be done and reanalysis results shall be considered as an initial results

3) Reduce designs, i.e. matrixing or bracketing, where the testing frequency is reduced or certain factor combination are not
tested at all, can be applied, if justified.

4) If the stability study at intermediate storage condition need to perform, same shall be mentioned in protocol.

4.4 STABILITY PROTOCOL:

4.4.1 Before starting the stability studies for a given reason, a Stability Protocol (SP) shall be prepared by QA Personnel and
approved by Quality control and Quality Assurance. QA personnel shall load the samples as per the stability protocol in stability
study chamber within 7 days from the date of approval of protocol.

Note: Annexure –1 shall be used as guidance for the preparation of stability protocol, contents shall be changed as per the
product requirement.

4.4.2 Based on the Stability Study Protocol, a Stability Study schedule shall be prepared by QA personnel.

4.4.3 Each protocol shall be identified with unique numbering system. It consists of 10 Characters.

4.4.3.1 First two characters are “SP” indicates stability protocol.

4.4.3.2 Third character indicates the market, “R” indicates regulatory market, and “D” indicates domestic market. Join us

4.4.3.3 Fourth characters is “/ “ (Slash).

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 3/13
10/2/24, 8:13 PM SOP for Stability Program
4.4.3.4 Next three characters are serial No for stability protocol starting from 001 for period from January to December.

4.4.3.5 Next characters is “ / “ (Slash ).

4.4.3.6 Last two characters indicates year ( ie 2008 as 08 etc.).

4.4.3.7 Control register for numbering of protocols shall be maintained by QA with details like S.No, Protocol No, Product name,
Batch No, reason for conducting stability study, Allotted by QA personnel, Approved by Head QA as per Annexure – 9.

4.5 SAMPLING, PACKING, LABELING

4.5.1 IPQA personnel shall perform sampling of the batches to be kept on stability studies, as per stability testing requirements.
Samples shall be representative of complete batch i.e. collect in regular interval.

Calculate the minimum sample quantity as per the below given Formula:

No of Units (e.g. Tablets/Capsules, etc) Required for one complete Analysis x 2 x Total No. of stations (Accelerated+
Intermediate+ Long Term)

Stability sample Should be labeled as per annexure 11.

Withdraw the sample in intact pack. If quantity of units (Tablets/Capsule) differs than the last full pack is to be withdrawn.

4.5.2 The stability samples wherever possible shall be kept in market pack only. In case of bulk pack etc. required number of
quantity of sample can be collected in a suitable container/closure system, which simulates the market pack as far as possible
and shall be labeled with all necessary details like Product, B. No, Mfg. Date, Exp. Date, loaded on and condition.

4.5.3 Separate samples shall be collected for microbiology if it is required.

4.5.4 Stability samples shall be kept in control storage area (below 25°C) until the approval of the batch / stability study
initiation.

4.6 STABILITY CHAMBERS MONITORING:

4.6.1 The stability chambers shall be monitored for temperature and relative humidity and records shall be maintained.

4.6.2 Take printouts of the environmental monitoring record by using the stability Data Acquisition Software every working day.

Note: Mean kinetic temperature (MKT) is defined as the isothermal temperature that corresponds to the kinetic effects of a
time-temperature distribution.

4.6.3 The yearly MKT for the preceding twelve months should be calculated every month.

4.6.4 If there is any excursion/deviation from the tolerance limits of temperature or RH.

4.6.5 Excursion that exceed the defined tolerance for more than 24 hour should be Documented and their impact shall be
assessed through incident report otherwise the excursion observed below 24 hour are recorded and concluded in Temperature
monitoring record.

4.6.6 Job maintenance request shall be sent to the maintenance department for rectification.

4.6.7 The breakdown and restoration of the stability chamber shall be well documented by the QA personnel and maintenance
department.

4.6.8 The “sign-in” and “sign-off” records shall be maintained for samples (in a log book), as and when the samples are
charged in and removed out from the stability chambers as per stability chamber usage log book (Annexure – 3).

4.6.9 Procedure for BackUp of Temperature and Relative Humidity Data from Stability Data Acquisition Software.

4.6.10 Procedure for Restore of Temperature and Relative Humidity BackUp Data to Stability Data Acquisition Software as per
requirement.

4.7 STABILITY SAMPLING AT SCHEDULE TIME POINT

4.7.1 Quality Assurance personnel shall withdraw the samples for analysis as per the stability study schedule (Annexure-2) and
details shall be entered in respective stability chambers log books (Annexure-3).

Note: Summary schedule shall be prepared from the stability study schedule (Annexure-2) and shall be verified. Summary
schedule shall be used at the time of withdrawal of stability samples.

After withdrawal and analysis of sample the remaining printed packaging material like show box, leaflets, empty strip, bottles
etc. shall be cut into pieces or with any other suitable means to destroy its identity and same shall be send to scrap for disposal
or shall be kept in west been kept outside of the stability chambers

4.7.2 Sampling of stability sample shall be done with in + 3 days form the schedule date. Join us

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 4/13
10/2/24, 8:13 PM SOP for Stability Program
4.7.3 QA shall raise the stability analysis request and report for analysis (Annexure – 4), Label the samples with sample for
testing (Annexure – 6) and send samples along with the request to Analyst(s) for analysis. The top part of the request above
the doted line shall be destroyed after receiving the record of analysis for Stability Study from Analyst(s)

Note: Sample shall kept below 25° C during the analysis period.

4.7.4 The tolerance allowed from the due date of analysis of stability sample (s) shall be 15 days from the date of sample
withdrawn from the stability chamber and submission of report to QA shall be 7 working day from completion of analysis, any
deviation from the target date shall be justified.

4.7.5 The remaining samples after complete testing at all intervals and samples of discontinued batches shall be disposed as
per standard procedure.

4.7.6 The stability study test results shall be properly recorded in the record of analysis for Stability Study Sheet. All primary
data print outs/chromatograms shall be checked and filed properly along with record of analysis.

4.8 REPORTING

4.8.1 The stability test results shall be recorded in the Stability analysis request and report by Analyst(s).

4.8.1.1 As soon as the analysis is completed and results are calculated Analyst(s) shall check the previous trending.

4.8.1.2 In case of any abnormalities are observed / significant change:

Prepared solutions shall not be discarded, incident report / OOS report shall be raised, and shall be investigated as case may
be.

4.8.2 In General “Significant Change” for a drug product (E.g. tablet / Capsule) is defined as:

4.8.2.1 A 5 % change in assay from its initial value or failure to meet the acceptance criteria for potency.

4.8.2.2 Any degradation product’s exceeding its acceptance criteria.

4.8.2.3 Failure to meet the acceptance criteria for appearance, physical attributes and functionality test (e.g. color, hardness).
However some changes in physical attributes may be expected under accelerated conditions as appropriate for the dosage
form.

4.8.2.4 Failure to meet the acceptance criteria for dissolution for 12 dosage units.

Note: For Stability indicating Parameter refer the stability specification for stability parameter to be check for stability of
individual product or/ otherwise refer the SOP “Procedure to list out test for stability Study”

4.8.3 After completion of analysis, Analyst(s) shall send back the stability analysis request and report along with analysis report
to QA Department for there review and compilation.

4.8.4 QA personnel shall check the report and results shall be compiled for each station in the summary report as per Annexure
8 with trend of previous station.

Note: Annexure –8 shall be used as a guidance for the preparation of stability summary report; Summary report can be
formatted as per requirement bases.

4.8.5 The trend of results shall be reviewed at each station within seven working days of submission of results from Analyst(s).
Graphical representation wherever applicable for critical stability parameters shall be prepared for all stations once in a year for
the period of January to December. The graphs are to be compiled within January of current year for review of previous year
Data.

4.8.6 In case of confirmed stability failure the same shall be communicated to Head of R & D, Head Corporate Quality and Head
of Regulatory Department (wherever required) by Head QA.

4.8.7 The stability study shall be discontinued in case of failure to comply with the specification. Written approval of Head QA
and Head corporate QA shall be taken to discontinue the stability study prior to study discontinuation.

4.8.8 The investigation for failure shall be conducted with the help of R & D. The investigation shall be extended to other
batches manufactured under similar condition and / or other batches, which are likely to be affected. The recall shall be
initiated whenever required as per SOP on ‘Product Recall’.

4.9 DISCONTINUATION OF STABILITY STUDY

4.9.1 Stability study shall be discontinued in case product related problem, product discontinued from the market or any other
reason with justification.

4.9.2 QA shall raise stability study discontinuation form (Annexure-5) duly approved by Head QA and Head CQA. An intimation
in this regard shall be sent to Head of QC, R & D, Regulatory and the Plant Head. Stability study discontinuation form shall be
kept along with the protocol.

4.10 EXPIRATION DATING/RETEST PERIOD Join us

4.10.1 QA shall propose on Expiration Dating of products based on available stability studies data as follows:

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 5/13
10/2/24, 8:13 PM SOP for Stability Program
4.10.2 In case of a new product/new process, with satisfactory accelerated data at 40°C ±2°C / 75%RH ±5% RH, of 3 months,
an Expiration of 2 years can be safely proposed.

4.10.3 The Expiration Dating of the product can be extended beyond 2 years, based on available Long term stability data.

4.11 DESTRUCTION OF STABILITY SAMPLES:

4.11.1 The following procedure will be followed for destruction of stability samples in case of discontinuation of stability study
and remaining samples if any after stability study completion at a particular condition.

4.11.2 Enter the withdrawal details of stability samples in the Stability Chamber Usage Log Book as per Annexure – 3.

4.11.3 Remove all strips / blister and keep it on one side and leaflets, show boxes and other paper materials on the other side.
Defoil the strip / blister. Remove the dosage form from the blister / strip / bottle into a separate double line poly bag. Label
them as “Non Recoverable Residue for Destruction”, and dispose it as per standard procedure.

4.11.4 Remains of blister / strip / bottle send them to scrap processing area in double line polyethylene bags duly labeled for
shredding and disposal.

Labels on bottle shall be crossed or destroyed by peeled off.

4.11.5 Cut all other pre-printed packing materials e.g. leaflet, show box, cartoon etc. into pieces and transfer the same to scrap
processing area in double line polyethylene bags duly labeled for shredding and disposal.

4.11.6 Maintain the record of destruction of the samples in the “Stability Sample Destruction Record register as per Annexure –
10.

4.12 Bracketing and Matrixing of Stability Samples:

4.12.1 Bracketing:

Under Bracketing, the design of a stability schedule such that only samples on the extremes of certain design factors (e.g.,
Strength, Container Size and / or Fill) are tested at all time points as in full design. The design assumes that the stability of any
intermediate level is represented by the stability of the extremes tested.

4.12.2 Matrixing :

Under Matrixing, the design of a stability schedule such that a selected sub set of the total number of possible sample for all
factor combination shall be tested at a specified time point. At the subsequent time point, another sub set of samples for all
factor combination shall be tested. The design assumes that the stability of each sub set of samples tested represents in the
stability of all samples at a given time point. The differences in the samples for the same drug product shall be identified as,
e.g. covering different batches, different strength, different sizes of the same container closure system, and possibly, in some
cases different container closure systems.

When a secondary packaging system contributes to the stability of the drug product, matrixing shall be performed across the
packaging systems.

Each storage condition shall be treated separately under its own matrixing design. Matrixing shall not be performed across test
attributes. However alternative matrixing designs for different test attributes shall be applied if justified.

All selected combinations of batch, strength, container size and fill, among other things, shall also be tested at 12 months. In
addition, data from at least three time points, including initial, shall be available for each selected combination through the first
12 months of the study. For matrixing at an accelerated or intermediate storage condition, care shall be taken to ensure testing
occurs at a minimum of three time points, including initial and final, for each selected combination of factors.

Note:References are – ICH Q1, SUPAC, Guideline for Industry – Stability Testing of Drug Substance and Drug Product

5.0 ANNEXURES:

Annexure-1 Specimen Stability Protocol

Annexure-2 Specimen format of Stability Study Schedule

Annexure-3 Specimen format of Stability Chamber usage log book

Annexure-4 Specimen format of Stability analysis request and report.

Annexure-5 Specimen format of Stability Study Discontinuation form

Annexure-6 Specimen format of Stability Sample for Analysis

Annexure-7 Responsibility of QA Stability Coordinator

Annexure–8 Specimen format of Stability Study Summary Report

Join us
Annexure–9 Specimen format of Register for Numbering of Protocols

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 6/13
10/2/24, 8:13 PM SOP for Stability Program
Annexure–10 Stability Sample Destruction Record

Annexure–11 Specimen format of Stability Study Sample label

Annexure–12 Intimation slip for Vendor change of API

Annexure–13 Stability study in case of container closure changes

Annexure–14 Stability Data Packages

===============================================

Annexure-1 Specimen Stability Protocol

Product:

CONTENTS

1.0 Objective

2.0 Responsibilities

3.0 Stability Plan

4.0 Procedure

4.1 Stability Sample Collection

4.2 Initiation of stability

4.3 Stability Sample Withdrawal

4.4 Compilation of stability data

1.0 OBJECTIVE:

The objective of this protocol is to conduct the stability studies as per the requirement to establish the stability and shelf life of
the product.

2.0 RESPONSIBILITY:

2.1 Quality Assurance:

To initiate the stability studies, loading and collection of samples as per the schedule, review and compile the stability data.

2.2 Analyst(s):

To analyze the samples and submit the reports to Quality Assurance Officer(s).

3.0 STABILITY PLAN:

Reason for conducting the stability Study:

3.1 Active Pharmaceutical Ingredient Details

Active Ingredient:

Name and address of the Manufacturer:

3.2 Batch Size:

3.3 Market:

3.4 Pack Details:

3.5 Container/ Closure System:

3.6 No. of units required at each condition (in duplicate):

25ºC/ 60% RH : 30ºC/ 65% RH : 40ºC/ 75% RH

3.7 Test interval According to the storage condition Join us

3.8 Test to be performed at each station

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 7/13
10/2/24, 8:13 PM SOP for Stability Program
4.0 PROCEDURE:

4.1 Stability sample collection:

4.1.1 IPQA personnel shall collect the samples for stability during packing and initiate stability studies; samples shall be
collected as per the SOP. The samples shall be twice the quantity sufficient for complete analysis for each interval.

4.2 Initiation of stability:

4.2.1 After release of batch, QA person shall load samples into stability chambers at respective storage conditions

4.2.2 Loading details of the samples

Batch Details

Container/ Quantity

No. of units

Batch No

Mfg.

Exp.

Loaded by

4.3 Stability sample withdrawal:

4.3.1 QA personnel shall withdraw the samples as per the schedule.

4.3.2 Sample withdrawal shall be done on or with in + 3 days of the scheduled due date.

4.3.3 After sampling, samples shall be forwarded to Analyst(s) for analysis along with Stability analysis request and report.

4.3.4 Analyst(s) shall analyze the samples as per Technical Analytical Document.

4.3.5 Samples shall be stored at below 25 Deg. C till the analysis is complete.

4.3.6 Once the analysis is completed, Analyst(s) shall give Analysis request and report along with record of analysis to Quality
Assurance Officer(s) for review and compile.

4.4 Compilation of Stability data

4.4.1 Concerned personnel of the Quality Assurance shall compile the data.

Annexure – 3 STABILITY CHAMBER USAGE LOG BOOK

Equipment No:

Conditions Maintained at:

Calibration Due Date:

USAGE DETAILS

Date Join us

Used for

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 8/13
10/2/24, 8:13 PM SOP for Stability Program
Entry time

Exit Time

Protocol No

Used by

Remarks

Annexure – 5 STABILITY STUDY DISCONTINUATION FORM (SSDF)

Name of the product

Manufacturing Location

Pack

Batch Number(s)

Manufacturing Date

Protocol No

Reason(s) for Discontinuation

Initiated By

Approved by Head QA

Head CQA

Annexure – 4 STABILITY ANALYSIS REQUEST AND REPORT

Product Name

Storage Condition

Batch No

Duration

Sample Quantity

Requested By / Date

Received By / Date

Content below the dotted line shall be send to Analyst and the above part shall be retained with Stability Coordinator

Date:

Product Name:

Generic Name:

Batch No:

Mfg. Date:

Exp. Date:

Storage Conditions:

Duration:

Pack:

Requested By:

Sample Quantity:
Join us
AR No.:

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 9/13
10/2/24, 8:13 PM SOP for Stability Program
TAD No/ Test Method Reference.:

S. No

Tests

Spec.

Results

Analyzed by:

Checked by:

Annexure – 6: Not provided here

Annexure – 7: Responsibility of QA Stability Coordinator

Receipt of Stability Sample from IPQA

Preparation of Stability Protocol

Loading of Sample in Stability Chamber

Make necessary entries in Stability Chamber Usage Log Book

Make necessary entries in Stability Study Schedule

Monitor Daily Environmental Condition (Temperature & Relative Humidity)

Withdrawal of Samples as per Stability Study Schedule

Preparation of Stability Analysis request and Report

Handover Stability Analysis request along with necessary samples to Analyst(s) for analysis

Receive and Review the Analytical Data

Prepare Summary Report

Annexure – 9 Stability Protocol Numbering Record

Sr. No.

Protocol No.

Product Name

Batch No.

Reason For Conducting Stability Study

Allotted by Date / Sign

Join us
Approved By (Head QA)

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 10/13
10/2/24, 8:13 PM SOP for Stability Program
Annexure – 10: Stability Sample Destruction Record

Sr. No.

Product

Batch No.

Condition

Qty. To be Destroyed

Reason

Destroyed by / Date

Approved By / Date

Annexure – 11 Stability Study Sample

Pack Style :___________

Date :________________

Sign :________________

Annexure – 12: Intimation slip for Vendor change of API

Name of material:

Quantity Received:

Manufacturer:

Date of intimation:

Supplier:

From: RM Store

To: QA Department

Please note that above material is issued in following product first time.

Product name: _____________________________________________

Batch No.: _____________________________________________

Mfg. Date: _____________________________________________

Exp. Date: __________________________________ ________

Note: This is for your information and further action

Prepared By:

Received By:

Annexure 13 Stability study in case of container closure changes

Type of change Definition Examples Stability

Data Packag
Changes that do not 1. Closure changes Adding or changing a child- Type 0
affect the protective resistant feature to a packaging
properties of the system or changing from a metal
Container / closure to a plastic screw cap, while the
system inner seal remains unchanged.
2. Changing the secondary Changing a carton. Type 0
packaging
3. Removal of non-drug Removing:
product material a. an insert.
b. a filler. Type 0 Type

Changing the shape of (Without changing the size) Type 0 Join us

container / closure

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 11/13
10/2/24, 8:13 PM SOP for Stability Program

Changing the size of a. Within the approved range of size . Type 0

container / closure
b. Out side the approved range of Type 2
size.

Changes that may 1. Adding or changing a a. Adding, or changing to, a Type 1

component to heat induction seal:
affect the
increase protection b. Adding or changing a desiccant
protective or filler. Type 2
within the same
properties of the c. Adding an over wrap or carton.
system.
container/closure Type 2

system 2. Changing the a. Using an approved or

compendium container or closure
manufacturer or equivalency protocol for: Type 1
formulation of a b. Without an approved
or compendium container or closure
container/closure Type 2
equivalency protocol.
component, including

bottle or blister resin,

cap liner, seal

laminate, desiccant,

filler, etc., within the

same system.

3. Changing to a For any solid oral drug product. Type 3

different container

and closure system

Note: Type 0, Type 1, Type 2, Type 3 are data packages which is as per Annexure 14
Annexure 14 Stability Data Packages
Stability Data package Stability Data at the time of Stability Commitmen
regulatory submission
None beyond the Regular
Type 0 None

Type 1 None First (1) production batch on

term condition.

And

Regular study.

Type 2 3 months of comparative First (1) production batch on

accelerated data and available long term condition.
term data on 1 batch with proposed
changed. And

Regular study.

Type 3 3 months of comparative First 3 production batch on

accelerated data and available long condition.
term data on 1 batch with proposed
changed. And

Regular study.

Regular study – Any one of the first three batch of the year and any one of the first three batch
after every 100th batch in a year shall be kept for long term stability study.

Tags: QA-SOP

 Facebook  Twitter    

 OLDER NEWER 
Handling of Out Of Trend (OOT) Operation and Cleaning of RO water System

Posted by: srikanth nagabiru

Join us

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 12/13
10/2/24, 8:13 PM SOP for Stability Program

You May Like These Posts

QA-SOP QA-SOP QA-SOP

SOP For Acceptance Quality Good Documentation Practices Intermediate and Finished Product
Level(AQL)  August 19, 2023 sampling SOP
 September 04, 2023  August 05, 2023

Post A Comment

0 Comments

To leave a comment, click the button below to sign in with Google.

SIGN IN WITH GOOGLE

TAGS
POPULAR POSTS //disable Text Selection and Copying
ANALYTICAL METHODS AR&D BOOKS
USP 2023[USP 46 and NF 41
DATA INTEGRITY ENGINEERING FR&D
 July 26, 2023

GUIDELINES METHOD VALIDATION

Water Content by KF
MICROBIOLOGY PHARMACOPOEA

 November 30, 2012 PRODUCTION QA-SOP QUALITY CONTROL

QUIZ STABILITY DATA EVALUATION

Retention sample or Control samples STABILITY GUIDELINES STABILITY STUDIES

management sop
 July 23, 2023 STRESS TESTING VALIDATION

VOLUMETRIC SOLUTIONS WAREHOUSE

Preparation and Standardization of
0.1M Silver Nitrate
 December 02, 2012
PERFECT TAG
Preparation and standardization of
0.1M Perchloric acid
 December 02, 2012

British Pharmacopoeia 2023

 November 02, 2023

Peak-Valley Ratio calculation

 November 25, 2012

Assay Calculation in HPLC

 September 23, 2012

Analysis of Raw Materials – SOP

 July 30, 2023

Calculation of Related Substances by

HPLC
 September 23, 2012

Created By Blogging | Distributed By Blogger Themes Home About Contact Us

Table of Contents Show all

Join us

https://www.pharmasopworld.com/2023/07/sop-for-stability-program.html 13/13